1. Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer
- Author
-
Ran Li, Yoshiko Iwamoto, Miles A. Miller, Sareh Parangi, Viswanath Gunda, Thomas Ng, Rainer H. Kohler, Mark Prytyskach, and Ralph Weissleder
- Subjects
Proto-Oncogene Proteins B-raf ,Antineoplastic Agents ,Antibodies, Monoclonal, Humanized ,Thyroid Carcinoma, Anaplastic ,B7-H1 Antigen ,030218 nuclear medicine & medical imaging ,Thyroid carcinoma ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Cell Line, Tumor ,Tumor-Associated Macrophages ,medicine ,Animals ,Radiology, Nuclear Medicine and imaging ,Anaplastic thyroid cancer ,Protein kinase A ,biology ,business.industry ,Immunity ,medicine.disease ,Magnetic Resonance Imaging ,Ferrosoferric Oxide ,Immune checkpoint ,Ferumoxytol ,Disease Models, Animal ,Reviews and Commentary ,030220 oncology & carcinogenesis ,Monoclonal ,Cancer research ,biology.protein ,Nanoparticles ,Female ,Antibody ,business - Abstract
Background Anaplastic thyroid cancer (ATC) is aggressive with a poor prognosis, partly because of the immunosuppressive microenvironment created by tumor-associated macrophages (TAMs). Purpose To understand the relationship between TAM infiltration, tumor vascularization, and corresponding drug delivery by using ferumoxytol-enhanced MRI and macrin in an ATC mouse model. Materials and Methods ATC tumors were generated in 6-8-week-old female B6129SF1/J mice through intrathyroid injection to model orthotopic tumors, or intravenously to model hematogenous metastasis, and prospectively enrolled randomly into treatment cohorts (
- Published
- 2021
- Full Text
- View/download PDF